-
Category
Proteins & Peptides
-
Long description
This peptide is the immunogen used to make Cat # X2751P. _x000B__x000B_Fibulin-1 is a modular glycoprotein component of elastic extracellular matrix fibers, basement membranes and blood. It can bind calcium, Fibronectin, Laminin, Nidogen and Fibrinogen. Estrogen exposure to ovarian cancer cell lines can upregulate Fibulin-1. Fibulin-2 is abundant in heart, placenta and ovarian tissue and binds several components of the extracelllar matrix including aggrecan, versican and brevican. Fibulin-3, also known as EFEMP1, is a secreted protein. Defects in the gene for Fibulin-3 cause the autosomal dominant disease Doyne honeycomb retinal dystrophy (DHRD, also known as malattia leventinese) which is characterized by yellow-white deposits (drusen) that accumulate under the retinal pigment epithelium. Fibulin-3 is not present at the site of drusen formation in normal eyes. Fibulin-5 is an integrin-binding extracellular matrix protein that mediates endothelial cell adhesion.
-
Antibody come from
Hybridoma produced by the fusion of splenocytes from BALB/c mice immunized with purified recombinant Fas antigen and fused with X63/Ag.8653 mouse myeloma cells
-
Other description
Provided as solution in phosphate buffered saline with 0.08% sodium azide.
-
Clone
not specified
-
Antigen antibody binding interaction
Fibulin-3 - Blocking Peptide
-
Antibody is raised in
see techfile
-
Antibody s reacts with
Blocking Peptide to Cat # X2751P
-
Antibody s reacts with these species
This antibody doesn't cross react with other species
-
Antibody s specificity
No Data Available
-
Application
Blocking Peptide
-
Antibody s suited for
Antibody can be used for flow cytometry. Optimal concentration should be evaluated by serial dilutions.
-
Storage
-20ºC
-
Relevant references
1) The 55-kD tumor necrosis factor receptor and CD95 independently signal murine hepatocyte apoptosis and subsequent liver failure. Author : Leist M; Gantner F; K unstle G; Bohlinger I; Tiegs G; Bluethmann H; Wendel A Source : Mol Med, 2(1):109-24 1996 Jan _x000B__x000B_2) Regulation of CD95 ligand expression: a key element in immune regulation? Author : Brunner T; Yoo NJ; Griffith TS; Ferguson TA; Green DR Source : Behring Inst Mitt, (97):161-74 1996 Oct _x000B__x000B_3)Expression of CD95 antigen and Bcl-2 protein in non-Hodgkin's lymphomas and Hodgkin's disease [published erratum appears in Am J Pathol 1996 Jul;149(1):346] Author : Nguyen PL; Harris NL; Ritz J; Robertson MJ Source : Am J Pathol, 148(3):847-53 1996 Mar _x000B__x000B_4) Relation of oxidative stress and glutathione synthesis to CD95(Fas/APO-1)-mediated apoptosis of adult T cell leukemia cells. Author : Kohno T; Yamada Y; Hata T; Mori H; Yamamura M; Tomonaga M; Urata Y; Goto S; Kondo T Source : J Immunol, 156(12):4722-8 1996 Jun 15 _x000B__x000B_5) Clonal deletion of major histocompatibility complex class I-restricted CD4+CD8+ thymocytes in vitro is independent of the CD95 (APO-1/Fas) ligand. Author : M uller KP; Mariani SM; Matiba B; Kyewski B; Krammer PH Source : Eur J Immunol, 25(10):2996-9 1995 Oct _x000B__x000B_6) Activation of the CD95 system increases with disease progression in human immunodeficiency virus type 1-infected children and adolescents. Author : B ohler T; B aumler C; Herr I; Groll A; Kurz M; Debatin KM Source : Pediatr Infect Dis J, 16(8):754-9 1997 Aug _x000B__x000B_7) Fc gammaRIII-mediated regulation of hematopoiesis in murine bone marrow cells by interleukin-3 and CD95 (Fas/Apo-1). Author : Yoshikawa H; Sakihama T; Nakajima Y; Tasaka K Source : Blood, 90(5):1911-9 1997 Sep 1 _x000B__x000B_8) Human autoreactive and foreign antigen-specific T cells resist apoptosis induced by soluble recombinant CD95 ligand. Author : Zipp F; Martin R; Lichtenfels R; Roth W; Dichgans J; Krammer PH; Weller M Source : J Immunol, 159(5):2108-15 1997 Sep 1 _x000B__x000B_9) The CD95 (APO-1/Fas) system mediates drug-induced apoptosis in neuroblastoma cells. Author : Fulda S; Sieverts H; Friesen C; Herr I; Debatin KM Research Center, Heidelberg. Source : Cancer Res, 57(17):3823-9 1997 Sep 1 _x000B__x000B_10) Differential CD95 expression and function in T and B lineage acute lymphoblastic leukemia cells. Author : Karawajew L; Wuchter C; Ruppert V; Drexler H; Gruss HJ; D orken B; Ludwig W. D. Source : Leukemia, 11(8):1245-52 1997 Aug
-
Protein number
see ncbi
-
Warnings
This product is intended FOR RESEARCH USE ONLY, and FOR TESTS IN VITRO, not for use in diagnostic or therapeutic procedures involving humans or animals. This datasheet is as accurate as reasonably achievable, but Nordic-MUbio accepts no liability for any inaccuracies or omissions in this information.
-
-
Test
You can block the antibody by the specific target amino acid sequence of peptide.
-
Properties
blocking peptide
-
Description
Peptides short amino acid chains or epitopes or blocking antagonists. The shortest peptides are dipeptides, consisting of 2 amino acids joined by a single peptide bond, followed by tripeptides, tetra peptides, ... till polypeptides that are long, continuous, and unbranched synthetic peptide chains. These biological oligomers and polymers can be Solid-phase peptide synthesis (SPPS), or in continue produced for custom peptide synthesis projects. The High-efficiency solid phase peptide synthesis (HE-SPPS) is give very low production costs.
